Antibody data
- Antibody Data
- Antigen structure
- References [13]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11921-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11921-1-AP, RRID:AB_874225
- Product name
- RASSF6 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated RASSF6 antibody (Cat. #11921-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Characterization of mouse embryonic fibroblasts derived from Rassf6 knockout mice shows the implication of Rassf6 in the regulation of NF-κB signaling.
MiR-496 promotes migration and epithelial-mesenchymal transition by targeting RASSF6 in colorectal cancer.
RASSF6 Is Downregulated In Human Bladder Cancers And Regulates Doxorubicin Sensitivity And Mitochondrial Membrane Potential Via The Hippo Signaling Pathway.
RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma.
Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.
The RASSF6 Tumor Suppressor Protein Regulates Apoptosis and Cell Cycle Progression via Retinoblastoma Protein.
BCL-XL binds and antagonizes RASSF6 tumor suppressor to suppress p53 expression.
RASSF6 downregulation promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal cancer.
Decreased level of RASSF6 in sporadic colorectal cancer and its anti-tumor effects both in vitro and in vivo.
Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery.
The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
Morishita M, Arimoto-Matsuzaki K, Kitamura M, Niimura K, Iwasa H, Maruyama J, Hiraoka Y, Yamamoto K, Kitagawa M, Miyamura N, Nishina H, Hata Y
Genes to cells : devoted to molecular & cellular mechanisms 2021 Dec;26(12):999-1013
Genes to cells : devoted to molecular & cellular mechanisms 2021 Dec;26(12):999-1013
MiR-496 promotes migration and epithelial-mesenchymal transition by targeting RASSF6 in colorectal cancer.
Wang H, Yan B, Zhang P, Liu S, Li Q, Yang J, Yang F, Chen E
Journal of cellular physiology 2020 Feb;235(2):1469-1479
Journal of cellular physiology 2020 Feb;235(2):1469-1479
RASSF6 Is Downregulated In Human Bladder Cancers And Regulates Doxorubicin Sensitivity And Mitochondrial Membrane Potential Via The Hippo Signaling Pathway.
Tan S, Bian X, Wu B, Chen X
OncoTargets and therapy 2019;12:9189-9200
OncoTargets and therapy 2019;12:9189-9200
RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma.
Zheng L, Zhao Z, Rong L, Xue L, Song Y
Journal of genetics and genomics = Yi chuan xue bao 2019 Oct 20;46(10):477-488
Journal of genetics and genomics = Yi chuan xue bao 2019 Oct 20;46(10):477-488
Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.
He Z, Zhao TT, Jin F, Li JG, Xu YY, Dong HT, Liu Q, Xing P, Zhu GL, Xu H, Miao ZF
Biochemical and biophysical research communications 2018 Sep 18;503(4):2340-2347
Biochemical and biophysical research communications 2018 Sep 18;503(4):2340-2347
The RASSF6 Tumor Suppressor Protein Regulates Apoptosis and Cell Cycle Progression via Retinoblastoma Protein.
Hossain S, Iwasa H, Sarkar A, Maruyama J, Arimoto-Matsuzaki K, Hata Y
Molecular and cellular biology 2018 Sep 1;38(17)
Molecular and cellular biology 2018 Sep 1;38(17)
BCL-XL binds and antagonizes RASSF6 tumor suppressor to suppress p53 expression.
Xu X, Iwasa H, Hossain S, Sarkar A, Maruyama J, Arimoto-Matsuzaki K, Hata Y
Genes to cells : devoted to molecular & cellular mechanisms 2017 Dec;22(12):993-1003
Genes to cells : devoted to molecular & cellular mechanisms 2017 Dec;22(12):993-1003
RASSF6 downregulation promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal cancer.
Zhou R, Qiu L, Liu X, Ling L, Li N, Zhou K, Sun J, Yan J, Tan C, Huang X, Han L, Yin L, Xiao G, Liu L
Oncotarget 2017 Aug 15;8(33):55162-55175
Oncotarget 2017 Aug 15;8(33):55162-55175
Decreased level of RASSF6 in sporadic colorectal cancer and its anti-tumor effects both in vitro and in vivo.
Chen E, Yang F, He H, Lei L, Liu R, Du L, Dong J, Wang M, Yang J
Oncotarget 2016 Apr 12;7(15):19813-23
Oncotarget 2016 Apr 12;7(15):19813-23
Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL, Li DD, Lin Q, Zhou Y, Zhou QB, Zeng B, Fu ZQ, Gao WC, Liu YM, Chen RW, Li ZH, Chen RF
World journal of gastroenterology 2015 Jun 7;21(21):6621-30
World journal of gastroenterology 2015 Jun 7;21(21):6621-30
RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Mezzanotte JJ, Hill V, Schmidt ML, Shinawi T, Tommasi S, Krex D, Schackert G, Pfeifer GP, Latif F, Clark GJ
Epigenetics 2014 Nov;9(11):1496-503
Epigenetics 2014 Nov;9(11):1496-503
Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery.
Wen Y, Wang Q, Zhou C, Yan D, Qiu G, Yang C, Tang H, Peng Z
Annals of surgical oncology 2011 Dec;18(13):3858-67
Annals of surgical oncology 2011 Dec;18(13):3858-67
The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F
Molecular cancer 2009 Jul 1;8:42
Molecular cancer 2009 Jul 1;8:42
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- U-937 cells were subjected to SDS PAGE followed by western blot with 11921-1-AP(RASSF6 antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Hela cells, using RASSF6 antibody 11921-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).
- Sample type
- cell line